• About
  • Advertise
  • Privacy & Policy
  • Contact
HK Businesswire
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    Federation secures prestigious Victorian International Education Award wins

    Federation secures prestigious Victorian International Education Award wins

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Meituan Reports Q3 2025 Results: Revenue Reaches RMB95.5 Billion as Annual Transacting Users Surpass 800 Million

    Xiaomi Founder Lei Jun Boosts Stake as Company Ramps Up Buybacks, Signaling Confidence

    Ant Group’s Multimodal AI Assistant LingGuang Surpasses 1 Million Downloads in Four Days

    Xiaomi Produces 500,000th EV in Record Time, CEO Lei Jun Pledges Focus on Safety and Delivery

    Morrison Foerster Report: ESG Committees and Climate Policy Gaining Traction Among Asia’s Largest GPs

    Xiaomi’s Double 11 GMV Surges Past RMB 29 Billion as It Claims Top Domestic Phone Sales for Third Year

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    Federation secures prestigious Victorian International Education Award wins

    Federation secures prestigious Victorian International Education Award wins

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Meituan Reports Q3 2025 Results: Revenue Reaches RMB95.5 Billion as Annual Transacting Users Surpass 800 Million

    Xiaomi Founder Lei Jun Boosts Stake as Company Ramps Up Buybacks, Signaling Confidence

    Ant Group’s Multimodal AI Assistant LingGuang Surpasses 1 Million Downloads in Four Days

    Xiaomi Produces 500,000th EV in Record Time, CEO Lei Jun Pledges Focus on Safety and Delivery

    Morrison Foerster Report: ESG Committees and Climate Policy Gaining Traction Among Asia’s Largest GPs

    Xiaomi’s Double 11 GMV Surges Past RMB 29 Billion as It Claims Top Domestic Phone Sales for Third Year

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
HK Businesswire
No Result
View All Result
Home News Business

Nvidia beats earnings expectations but shares fall

Purton L by Purton L
27 August 2025
in Business, News
0
Nvidia beats earnings expectations but shares fall
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter
AI powerhouse Nvidia on Wednesday reported quarterly earnings that beat expectations, but shares slipped amid concerns about an AI chip spending bubble and the company’s stalled business in China.

The California-based firm posted a profit of US$26.4 billion on record revenue of US$46.7 billion in the recently ended quarter, driven by intense demand for chips from major tech companies powering AI datacenter computing.

However, while revenue increased significantly year-over-year, Nvidia’s Data Centre revenue declined 1 percent from the previous quarter.

The drop was driven by a US$4 billion decrease in sales of H20 chips-specialized processors the company designed for the Chinese market, according to the earnings report.

For the current quarter, Nvidia projected US$54 billion in revenue but said its forecast assumes no H20 sales.

Nvidia’s high-end GPUs remain in hot demand from tech giants building data centres for artificial intelligence applications.

However, investors are questioning whether the massive AI investments are sustainable.

“The data centre results, while massive, showed hints that hyperscaler spending could tighten at the margins if near-term returns from AI applications remain difficult to quantify,” said Emarketer analyst Jacob Bourne.

“At the same time, US export restrictions are fueling domestic chipmaking in China.”

Nvidia shares fell slightly more than 3 percent in after-market trading.

The earnings report comes amid market worries about an AI spending bubble that could burst and hurt the chip giant’s fortunes.

Nvidia serves as a bellwether for the AI market and became the first company to reach US$4 trillion in market value last July.

Earlier this month, President Donald Trump confirmed that Nvidia would pay the United States 15 percent of its revenues from sales of certain AI chips to China.

Beijing has responded by expressing national security concerns about Nvidia chips and urging Chinese businesses to rely on local semiconductor suppliers instead.

Nvidia developed the H20 – a less powerful version of its AI processing units – specifically for export to China to address US concerns that its top-tier chips could be used for weapons development or AI applications. (AFP)

Tags: BusinessFinance
Purton L

Purton L

Read More

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

8 December 2025
Federation secures prestigious Victorian International Education Award wins

Federation secures prestigious Victorian International Education Award wins

8 December 2025
  • Trending
  • Comments
  • Latest
Tai Po fire death toll climbs to 44, 56 injured

Tai Po fire death toll climbs to 44, 56 injured

26 November 2025
No for now on women deacons, Vatican commission says

No for now on women deacons, Vatican commission says

4 December 2025

Ant Group’s Multimodal AI Assistant LingGuang Surpasses 1 Million Downloads in Four Days

23 November 2025
Hang Seng Indexes Company and Cyberport Partner to Drive Gen-AI Adoption in Index Calculation

Hang Seng Indexes Company and Cyberport Partner to Drive Gen-AI Adoption in Index Calculation

4 November 2025
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

8 December 2025
Federation secures prestigious Victorian International Education Award wins

Federation secures prestigious Victorian International Education Award wins

8 December 2025
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

8 December 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

8 December 2025

Recent News

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

8 December 2025
Federation secures prestigious Victorian International Education Award wins

Federation secures prestigious Victorian International Education Award wins

8 December 2025
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

8 December 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

8 December 2025
HK Businesswire

Stay ahead with the latest insights on Hong Kong’s economy, finance, and investments. From market trends to policy updates, we bring you in-depth analysis and expert opinions.

📩 Subscribe to our newsletter for exclusive updates.
📍 Follow us on social media for real-time news.
📧 Contact us: info@hongkong-invest.com

Follow Us

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2025 by HKBusinesswire.com

No Result
View All Result

© 2025 by HKBusinesswire.com